Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction

FEBS Journal

Volumn 273, Issue 16, 2006, Pages 3837-3849

  Dudich, Elena ^a,b   Semenkova, Lidia ^a,b   Dudich, Igor ^a,b   Denesyuk, Alexander ^c   Tatulov, Edward ^b   Korpela, Timo ^d  

^a Institute of Immunology   (Russian Federation)

^b JSC BioSistema   (Russian Federation)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

^d Turku University   (Finland)

Author keywords

fetoprotein; Apoptosis; Apoptosome; Caspases; X linked inhibitor of apoptosis protein

Indexed keywords

ALPHA FETOPROTEIN; CASPASE 3; CASPASE 9; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL FREE SYSTEM; CELL LYSATE; CONTROLLED STUDY; CYTOSOLIC FRACTION; DOWN REGULATION; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME RECONSTITUTION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR CELL;

ALPHA-FETOPROTEINS; APOPTOSIS; BINDING, COMPETITIVE; CASPASE 3; CASPASE 9; CASPASES; CELL LINE; CELL-FREE SYSTEM; HUMANS; PROTEIN BINDING; RECOMBINANT PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33746758269     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2006.05391.x     Document Type: Article

References (66)

1. Reed JC (1999) Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11, 68-75.
2. Hickman JA (2002) Apoptosis and tumorigenesis. Curr Opin Genet Dev 12, 67-72.
3. Shi Y (2004) Caspase activation inhibition, and reactivation: a mechanistic view. Protein Sci 13, 1979-1987.
4. Oliver L & Vallette FM (2005) The role of caspases in cell death and differentiation. Drug Resist Updates 8, 163-170.
5. Fuentes-Prior P & Salvesen GS (2004) The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 384, 201-232.
6. Cory S, Huang DC & Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590-8607.
7. Salversen GS & Duckett CS (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3, 401-410.
8. Wright CW & Duckett CS (2005) Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 115, 2673-2678.
9. Schimmer AD, Dalili S, Batey RA & Riedl SJ (2006) Targeting XIAP for the treatment of malignancy. Cell Death Differ 13, 179-188.
10. Scott FL, Denault JB, Reidl SJ, Shin H, Renatus M & Salvesen GS (2005) XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 24, 645-655.
11. Sun H, Nikolovska-Coleska Z, Chen J, Yang C, Tomita Y, Pan H, Yoshioka Y, Krajewski K, Roller PP & Wang S (2005) Structure-based design, synthesis and biochemical testing of novel and potent Smac peptidomimetics. Bioorg Med Chem Lett 15, 793-797.
12. Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F, Houghten R, Pinilla C & Reed JC (2004) Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 279, 48168-48176.
13. Oost TK, Sun C, Armstrong R, Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET et al. (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47, 4417-4426.
14. Varshavsky A (2005) Regulated protein degradation. Trends Biochem Sci 30, 283-286.
15. Vaux DL & Silke J (2005) IAPs - the ubiquitin connection. Cell Death Differ 12, 1205-1207.
16. Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64, 7183-7190.
17. Du C, Fang M, Li Y, Li L & Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42.
18. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes-Alnemri T et al. (2002) Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts IAP-caspase interaction. J Biol Chem 277, 432-438.
19. Hegde R, Srinivasula SM, Datta P, Madesh M, Hoshino S & Alnemri E (2003) The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem 278, 38699-38706.
20. Liston P, Fong WG, Kelly N, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW & Korneluk RG (2001) Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 3, 128-133.
21. Lotan R, Rotem A, Gonen H, Finberg JP, Kemeny S, Steller H, Ciechanover A & Larisch S (2005) Regulation of the proapoptotic ARTS protein by ubiquitin-mediated degradation. J Biol Chem 280, 25802-25810.
22. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee RA, Robbins PD, Fernandes-Alnemri T, Shi Y & Alnemri ES (2001) A conserved XIAP interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112-116.
23. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ & Kaufmann SH (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277, 44236-44243.
24. Semenkova LN, Dudich EI & Dudich IV (1997) Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Tumor Biol 18, 261-274.
25. Dudich EI, Semenkova LN, Gorbatova EA, Dudich IV, Khromykh LM, Tatulov EB, Grechko GK & Sukhikh GT (1998) Growth-regulative activity of alpha-fetoprotein for different types of tumour and normal cells. Tumor Biol 19, 30-40.
26. Dudich EI, Semenkova LN, Dudich IV, Gorbatova EA, Tokhtamysheva N, Tatulov EB, Nikolaeva MA & Sukhikh GT (1999) a-Fetoprotein causes apoptosis in tumour cells via a pathway independent of CD95, TNFR1 and TNFR2 through activation of caspase-3-like proteases. Eur J Biochem 266, 1-13.
27. Dudich I, Tokhtamysheva N, Semenkova L, Dudich E, Hellman J & Korpela T (1999) Isolation and structural and functional characterization of two stable peptic fragments of human alpha-fetoprotein. Biochemistry 8, 10406-10414.
28. Semenkova LN, Dudich EI, Dudich IV, Tokhtamisheva NA, Tatulov EB, Okruzhnov YV, Garcia-Foncillas J, Palop-Cubillo JA & Korpela TK (2003) Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. Eur J Biochem 270, 276-282.
29. Deutsch HF (1991) Chemistry and biology of α-fetoprotein. Adv Cancer Res 56, 253-312.
30. Mizejewsky GJ (2002) Biological role of a-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2, 89-115.
31. Mizejewsky GJ (2001) Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med 226, 377-408.
32. Laborda J, Naval J, Allouche M, Calvo M, Georgoulias V, Mishai Z & Uriel J (1987) Specific uptake of alpha-fetoprotein by malignant human lymphoid cells. Int J Cancer 40, 314-318.
33. Deutsch HF (1994) The uptake of adriamycin-arachidonoc acid complexes by human tumor cells in the presence of a-fetoprotein. J Tumor Marker Oncol 9, 11-15.
34. Geuskens M, Dupressoir T & Uriel J (1992) A study, by electron microscopy, of the specific uptake of alpha-fetoprotein by mouse embryonic fibroblasts in relation to in vitro aging, and by human mammary epithelial tumor cells in comparison with normal donor's cells. J Submicrosc Cytol Pathol 23, 59-66.
35. Alava MA, Iturralde M, Lampreave F & Pineiro A (1999) Specific uptake of alpha-fetoprotein and albumin by rat Mor hepatoma cells. Tumor Biol 20, 52-64.
36. Moro R, Tamaoki T, Wegmann TG, Longenecker BM & Laderoute MP (1993) Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-fetoprotein receptor. Tumor Biol 14, 116-130.
37. Li M, Liu X, Zhou S, Li P & Li G (2005) Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes. BMC Cancer 5, 96-104.
38. Bennett JA, Semeniuk DJ, Jacobson HI & Murgita RA (1997) Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. Breast Cancer Res Treat 45, 169-179.
39. Bennet JA, Zhu S, Pagano-Mirarchi A, Kellom TA & Jacobson HI (1998) a-Fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. Clin Cancer Res 4, 2877-2884.
40. Sonnenschein C, Ucci AA & Soto AM (1980) Inhibition of growth of transplantable rat mammary tumors. Probable role of a-fetoprotein. J Natl Cancer Inst 64, 1141-1146.
41. Um SH, Mulhall C, Alisa A, Ives AR, Karani J, Williams R, Bertoletti A & Behboudi S (2004) α-Fetoprotein impairs APS function and induces their apoptosis. J Immunol 173, 1772-1778.
42. Muehlemann M, Miller KD, Dauphinee M & Mizejewski GJ (2005) Review of growth inhibitory peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis. Cancer Metastasis Rev 24, 441-467.
43. Dudich EI, Benevolensky SV, Marchenko AN, Zatcepin SS, Dudich DI, Koslov DI, Shingarova LN, Dudich IV, Semenkova LN & Tatoulov EB (2005) Recombinant alpha-fetoprotein, method and means for preparation thereof, compositions on the base of thereof and use thereof. International PCT No PCT/RU 2005/000369.
44. Morinaga T, Sakai M, Wegmann TG & Tamaoki T (1983) Primary structures of human alpha-fetoprotein and its mRNA. Proc Natl Acad Sci USA 80, 4604-4608.
45. Fu J, Jin Y & Arend LJ (2003) Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J Biol Chem 52, 52660-52672.
46. Li Q, Liston P, Schokman N, Ho JM & Moyer RW (2005) Amsacta moorei entomopoxvirus inhibitor of apoptosis suppresses cell death by binding Grim and Hid. J Virol 79, 3684-3691.
47. Huang Y, Rich RL, Myszka DG & Wu H (2003) Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. J Biol Chem 278, 49517-49522.
48. Sugio S, Kashima A, Mochizuki S, Noda M & Kobayashi K (1999) Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng 12, 439-446.
49. Sun C, Cai M, Gunasekera AH, Meadows RP, Wang H, Chen J, Zhang H, Wu W, Xu N, Ng SC & Fesik SW (1999) NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401, 818-822.
50. Sun C, Cai M, Meadows RP, Xu N, Gunasekera AH, Herrmann J, Wu JC & Fesik SW (2000) NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 275, 33777-33781.
51. Goldstein JC, Waterhouse NJ, Juin P, Evan GI & Green DR (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature Cell Biol 2, 156-162.
52. Zeuner A, Eramo A, Peschle C & De Matia R (1999) Caspase activation without death. Cell Death Differ 6, 1075-1080.
53. Oliver L, LeCabellec MT, Pradal G, Meflah K, Kroemer G & Vallette FM (2005) Constitutive presence of cytochrome c in the cytosol of a chemoresistant leukemic cell line. Apoptosis 10, 277-287.
54. Brustugun OT, Fladmark KE, Doskeland SO, Orrenius S & Zhivotovsky B (1998) Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2. Cell Death Differ 5, 660-668.
55. Jäätela M (1999) Escaping cell death: survival proteins in cancer. Exp Cell Res 248, 30-43.
56. Huang Y, Rich RL, Myszka DG & Wu H (2003) Requirement of both the second and third domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. J Biol Chem 49, 49517-49522.
57. Yang L, Cao Z, Yan H & Wood WC (2003) Coexistence of high levels of apoptotic signaling and inhibitors of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 63, 6815-6924.
58. Von Ahsen O, Waterhouse NJ, Kuwana T, Newmeyer DD & Green DR (2000) The 'harmless' release of cytochrome c. Cell Death Differ 7, 1192-1199.
59. Shiraki K, Sugimoto K, Yamanaka Y, Yamaguchi Y, Saitou Y, Ito K, Yamamoto N, Yamanaka T, Fujikawa K, Murata K et al. (2003) Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinima. Int J Mol Med 12, 705-708.
60. Liu X & Wang X (2000) In vitro assays for caspase-3 activation and DNA-fragmentation. In Methods in Enzymology (Colowick SP & Kaplan O, eds), Vol. 322 pp. 177-183. Academic Press, New York.
61. McLellan T (1982) Electrophoresis buffers for polyacrylamide gels at various pH. Anal Biochem 126, 94-99.
62. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24, 945-949.
63. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN & Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28, 235-242.
64. Corpet F (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16, 10881-10890.
65. Press WH, Flannery BP, Teukolsky SA & Vetterling WT (1988) Numerical Recipes in C, the Art of Scientific Computing. Cambridge University Press, Cambridge.
66. Powell MJD (1977) Restart procedures for the conjugate gradient method. Mathemat Programming 12, 241-254.